Immunic, Inc. (NASDAQ:IMUX) Receives Average Recommendation of “Buy” from Brokerages

Shares of Immunic, Inc. (NASDAQ:IMUX) have been assigned an average rating of “Buy” from the six research firms that are covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $12.25.

A number of equities research analysts recently commented on IMUX shares. StockNews.com cut shares of Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th. EF Hutton Acquisition Co. I raised Immunic to a “strong-buy” rating in a research report on Monday, September 16th. Leerink Partners reissued an “outperform” rating and issued a $5.00 price objective on shares of Immunic in a report on Monday, September 9th. B. Riley began coverage on shares of Immunic in a report on Tuesday, August 27th. They set a “buy” rating and a $6.00 price objective on the stock. Finally, Leerink Partnrs upgraded shares of Immunic to a “strong-buy” rating in a research report on Monday, September 9th.

Insiders Place Their Bets

In other news, Director Richard Alan Rudick bought 87,300 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The shares were acquired at an average price of $1.15 per share, with a total value of $100,395.00. Following the acquisition, the director now owns 87,300 shares of the company’s stock, valued at approximately $100,395. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 3.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. BVF Inc. IL purchased a new position in shares of Immunic during the first quarter worth about $11,752,000. Janus Henderson Group PLC bought a new stake in Immunic during the first quarter valued at approximately $9,266,000. Vanguard Group Inc. grew its stake in Immunic by 100.7% in the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after buying an additional 1,703,047 shares in the last quarter. Ikarian Capital LLC increased its holdings in shares of Immunic by 258.3% in the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after buying an additional 1,162,378 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after buying an additional 42,383 shares in the last quarter. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

Immunic Stock Performance

NASDAQ IMUX opened at $1.10 on Friday. The company has a market capitalization of $99.09 million, a PE ratio of -0.89 and a beta of 1.88. Immunic has a 52-week low of $0.97 and a 52-week high of $2.11. The company has a 50-day simple moving average of $1.40 and a 200 day simple moving average of $1.34.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.